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Abstract 
BACKGROUND: After coronary artery bypass graft (CABG) surgery, heart failure is still major problem. The 
valuable marker for it is needed. 
AIM: Evaluating the role of serial NT-proBNP level in prognosis and follow-up treatment of acute heart failure after 
CABG surgery.  
METHODS: The prospective, analytic study evaluated 107 patients undergoing CABG surgery at Ho Chi Minh 
Heart Institute from October 2012 to June 2014. Collecting data was done at pre- and post-operative days with 
measuring NT-proBNP levels on the day before operation, 2 hours after surgery, every next 24 h until the 5
th 
day, 
and in case of acute heart failure occurred after surgery.  
RESULTS: On the first postoperative day (POD1), the NT-proBNP level demonstrated significant value for AHF 
with the cut-off point = 817.8 pg/mL and AUC = 0.806. On the second and third postoperative day, the AUC value 
of NT- was 0.753 and 0.751. It was statistically significant in acute heart failure group almost at POD 1 and POD 2 
when analyzed by the doses of dobutamine, noradrenaline, and adrenaline (both low doses and normal doses). 
CONCLUSION: Serial measurement of NT-proBNP level provides useful prognostic and follow-up treatment 
information in acute heart failure after CABG surgery. 
 
 
 
 
 
Introduction 
 
 Acute heart failure emerged as the primary 
cause of mortality after heart surgery in general and 
CABG surgery in particular [1]. It needs to early 
recognize before operation that helps clinicians 
consider patients who had heart failure into subgroups 
and allocate resources to maximize benefit from 
treatment and minimize risks such as adverse events. 
To predict early outcomes from cardiac surgery, both 
clinical tools (scoring systems) and biochemical tests 
were used. The two most common scoring systems 
were the EuroSCORE [2] and the Parsonnet score [3]. 
Although frequently used, it also had some limitations 
[4], [5]. To resolve, some biochemical tests were 
considered. Among that, NT-proBNP was emerged as 
one of the promise markers in heart disease, 
especially in heart failure [6]. It was used to predict 
postoperative outcomes in heart surgery in both early 
[7] and long-term effects [8]. The Canadian guideline 
recommended using it in persons with HF as a 
prognostic factor [9].  
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 The guideline of ESC also remarked NT-
proBNP as one of prognostic factors [10]. Moreover, 
in CABG surgery, it independently predicted 
postoperative outcome [11]. In combination with 
existing clinical tools such as EuroSCORE II, it 
showed more accuracy than using it alone [12]. 
 Besides predictive ability before 
cardiac surgery [13], NT-proBNP levels contribute a 
valuable role in heart failure management [14] evenly 
in acute or unstable state [15]. Elevating NT-proBNP 
levels in these situations was associated with poor 
clinical outcomes [16], [17]. To optimize 
medical therapy, serial NT-proBNP measurement was 
used in stable CHF patients [18]. But in acute heart 
failure after CABG surgery, data of this biochemical 
marker were too limited.  
 Therefore, this study aimed to evaluate the 
serial NT-proBNP level that could provide prognostic 
and follow-up treatment information of acute heart 
failure after CABG surgery. 
 
 
Materials and Methods  
 
 We conducted this prospective study on 107 
patients who underwent CABG surgery at Ho Chi 
Minh Heart Institute from October 2012 to June 2014. 
Inclusion criteria included patients with established 
diagnoses of coronary artery stenosis based on 
angiography; aged 18 and older; consultation of 
internal medicine and surgery, and indication for 
CABG according to the recommendation American 
Internal Medicine Association (ACC/AHA/ACP /ASIM).  
 The exclusion criteria were: aged <18; 
damage of 1 or 2 branches of coronary artery; overall 
50 - 60% of coronary artery stenosis with excepting 
main body; < 50% diameter of coronary artery 
stenosis; concomitant cardiac surgery such as valve 
surgery and septal surgery ; renal function 
insufficiency (eGFR <30 ml/min/1.73m
2
). 
 
 Monitoring  
 Chronic heart failure (CHF) before surgery 
was diagnosed according to the Framingham criteria, 
while postoperative diagnosis of acute heart failure 
(AHF) was followed the guidelines of Viet Nam Heart 
Association 2015 with staging A, B, C and D 
according to ACC/AHA and grading according to 
NYHA. Indexes in heart failure were recorded in 
echocardiography. The main prognosis factor of heart 
failure after surgery were EuroSCORE and the level of 
serial NT-proBNP. NT-proBNP level was quantified at 
the Department of Biochemistry at Ho Chi Minh Heart 
Institute, using the electrochemiluminescence 
immunoassay (ECLIA). The optimal cutting points of 
NT-proBNP to determine acute heart failure for ages 
younger than 50, from 50 to 75 and older than 75 
years are 450, 900 and 1800 pg/ml, respectively. The 
NT-proBNP-independent age cut point less than 300 
pg/ml had a negative diagnostic value to rule out 
acute heart failure at 98%.Collecting time was noted 
as following: B0: the day before surgery; B1: 2 hours 
after surgery; B2, B3, B4, B5 were collected at 8 a.m 
on days 2, 3, 4, 5 after surgery; Bx: at the time of 
expression of cardiac dysfunction (continuous 
monitoring of cardiac index on the Flo-Trac system) or 
when the patient presents with acute heart failure. 
 We also recorded data about dosage and 
using time of dobutamine, noradrenaline, and 
adrenaline in collecting time after surgery to follow-up 
treatment. Collecting time was noted as following: N0: 
the day before surgery; N1: 2 hours after surgery; N2, 
N3, N4, N5 were collected at 8 a.m on days 2, 3, 4, 5 
after surgery. In addition, follow-up at times when 
patients showed cardiac impairment or when acute 
heart failure occurred. 
 
 Statistical analysis 
 Statistical analysis was performed by Epidata 
6 and STATA version 14.0 software.  
 Descriptive analysis presented as mean ± 
standard deviation (95% confidence interval). Testing 
t-Student/Mann-Withney U test/Wilcoxon/ANOVA and 
Chi-square/ Fisher's exact test, Kolmogorov test, 
Person correlation, single and multivariate linear 
regression methods used in the study. p-value < 0.05 
was known as statistically significant. 
 
 
Results 
 
 Out of 107 patients, 67.3% was male. Medical 
history was chest pain (98.1%), hypertension (77.6%), 
myocardial ischemia (77.6%), heart failure (28.0%), 
diabetes (24.3%), myocardial infarction (9.4%), 
dyslipidemia (7.5%), arrhythmias (4.7%), COPD 
(3.7%), and renal failure (1.9%). Demographics of CHF 
before surgery and AHF after surgery showed in Table 
1. 
Table 1: Demographics of chronic heart failure before surgery and 
acute heart failure after surgery 
Pre-operative 
condition 
Post-operative condition 
 Without AHF AHF Total p-value 
Without CHF 64 (78.1 %) 7 (28.0 %) 71 (66.4 %) < 0.0001 
CHF 18 (21.9 %) 18 (72.0 %) 36 (33.6 %) < 0.0001 
Total 82 (76.6 %) 25 (23.4 %) 107 (100%) < 0.0001 
Note: CHF: Chronic heart failure; AHF: Acute heart failure. 
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On the first postoperative day (POD1), the NT-
proBNP level demonstrated significant value for AHF 
in patients undergoing CABG surgery with the cut-off 
point = 817.8 pg/mL and AUC = 0.806 (95% CI = 0.71 
to 0.90; p<0.0001; sensitivity = 70%; and specificity = 
80.5%). The values of NTproBNP for AHF on the 
second and third postoperative days (POD 2 and 
POD3) showed detail in Table 2.  
Table 2: Cut-off values of NT-proBNP according to Euro-score 
Post-
operative day 
(POD) 
Cut-off 
value 
Sensitivity Specificity AUC 
(95% CI) 
Youden – 
Index 
POD 1 817.8 70.0 % 80.5 % 0.806 (0.71 – 0.90) 0.505 
POD 2 2,516 66.7 % 77.9 % 0.753 (0.64 – 0.87) 0.446 
POD 3 3,556 60.0 % 81.6 % 0.751 (0.64 – 0.86) 0.416 
Note: AUC: Area under the curve; CI: Confidence Interval. 
 
 Table 3 performed detail analysis of NT-
proBNP cut-off value according to EuroSCORE.  
Table 3: Detail analysis of cut-off value of NT-proBNP 
according to EuroSCORE 
 EuroSCORE Cut-off NT-proBNP 
L and I 
risk 
High 
risk 
Indexes ≤  
Cut-off 
>  
Cut-off 
Indexes 
Sen Spe Acc P-
value 
Sen Spe Acc P-
value 
Pre-
operative 
Cut-off 
(508.8 
pg/ml) 
Without 
CHF (71) 
58 (81.7) 13(18.3) 47.2 81.7 70.1 0.002 56 (78.9) 15 (21.1) 80.6 78.9 79.44 0.000 
CHF (36) 19 (52.8) 17 (47.2) 7 (19.4) 29 (80.6) 
POD 1 
Cut-off 
(871.8 
pg/ml) 
No AHF 
(94) 
73 (77.7) 21 (22.3) 77.7 69.2 76.64 0.002 70 (74.5) 24 (25.5) 74.5 92.3 76.64 0.000 
AHF 
(13) 
4 (30.8) 9 (69.2) 1 (7.7) 12 (92.3) 
POD 2  
Cut-off 
(2516 
pg/ml) 
No AHF 
(98) 
74 (75.5) 24(24.5) 75.5 66.7 74.8 0.014 68(69.4) 30(30.6) 69.4 77.8 70.1 0.008 
2(22.2) 7 (77.8) 
AHF (9) 3 (33.3) 6 (66.7) 
POD 3 
Cut-off 
(3556 
pg/ml) 
Without 
AHF(104) 
76(73.1) 28(26.9) 66.7 73.1 72.9 0.189 74(71.8) 29(28.2) 100 71.8 72.6 0.026 
AHF (3) 1 (33.3) 2 (66.7) 0 (0)  3 (100) 
Note: Sensitivity = Sen; Specificity = Spe ;Accurac = ACC , POD: Postoperative day; CHF: 
Chronic heart failure; AHF: Acute heart failure; Low and Intermediate risk = L and I risk. 
 
 To follow-up treatment, the general dosage 
and using time of inotrope was shown in Table 4.  
Table 4: Dosage and using time of inotrope (µg/kg/min) 
Factors 
Post-operative condition p-values 
Without AHF 
(n=82) 
AHF 
(n=25) 
 
Noradrenalin 
 Dosage 0.85 ± 1.59 0.14 ± 0.12 0.75
f
 
Using time 43.1 ± 28.9 112.9 ± 37.5 0.000
c
 
 
Dobutamine 
 
 Dosage 3.32 ± 1.82 6.25 ± 2.47 0.000
f
 
Using time 29.1 ± 28.2 101.1 ± 47.3 
0.000
f
 
Adrenalin 
 
 Dosage 0.026 ± 0.048 0.15 ± 0.15 0.000
f
 
Using time 16.6 ± 30.7 82.9 ± 55.6 0.000
f
 
Note: AHF: Acute heart failure. 
 
 More detail showed in Table 5 (dobutamine), 
table 6 (noradrenaline), and table 7 (adrenaline). The 
level of NT-proBNP level in AHF group was 
statistically significant compared to the without AHF 
group at POD 1 and POD 2 when analyzed by the 
normal doses of dobutamine. In low doses, it just 
showed statistically significant at POD 2 (Table 5). In 
AHF group it was statistically significant compared to 
the without AHF group at POD 1 and POD 2 when 
analyzed by the low doses of noradrenaline. In low 
doses, it did not show statistically significant at POD 
all three days after surgery (Table 6).  
 
Table 5: Level of serum NT-proBNP and dobutamine doses 
Time 
Dobutamin doses 
Post-operative condition 
p-values 
Without AHF AHF 
POD 1 Low doses (< 5 µg) 496.1 ± 609.9 2885 0.1
f
 
Normal doses (5-15 µg) 1.077.5 ± 2.154.5 2.499.8 ± 1.646.7 0.000
f
 
p-values 0.041
f
 0.59
f
  
POD 2 Low doses (< 5 µg) 1.956.8 ± 1.728.9 6.088 ± 4.774.8 0.023
f
 
Normal doses (5-15 µg) 3.465.2 ± 3.224.7 9.387.5 ± 8.623.8 0.036
f
 
p-values 0.049
f
 0.796
f
  
POD 3 Low doses (< 5 µg) 3.653.3 ± 4.984.2   
Normal doses (5-15 µg) 5.797.8 ± 3.937 8.123.7 ± 4.636.0 0.393
f
 
p-values 0.001
f
   
Note: POD: Post-operative day; AHF: Acute heart failure.; f. Mann-Withney U test. 
 
 When analyzed by the normal doses of 
adrenaline, in AHF group it was statistically significant 
compared to the without AHF group at POD 1 and 
POD 2.  
Table 6: Level of serum NT-proBNP and noradrenalin doses 
Time 
Noradrenalin dosage 
Post-operative condition 
p-values 
Without AHF AHF 
POD 1 Low dosage (<0.01 µg) 862.7 ± 1.855.5 2.447.2 ± 628.5 0.0001
f
 
Normal dosage (≥0.01 µg) 749.8 ± 871.9 2.578.7 ± 2.172.9 0.062
f
 
p-values 0.7
f
 0.81
f
  
POD 2 Low dosage (<0.01 µg) 2.335.5 ± 2.436.2 9.252.8 ± 9.681.3 0.014
f
 
Normal dosage (≥0.01 µg) 3.509 ± 2751.1 7.081.3 ± 4.235.8 0.073
f
 
p-values 0.03
f
 0.807
f
  
POD 3 Low dosage (<0.01 µg) 3.952.7 ± 5.067.4 13.415 0.13
f
 
Normal dosage (≥0.01 µg) 5.804.9 ± 3.476.9 5.478 ± 994.2 0.89
f
 
p-values 0.003
f
 0.221
f
  
Note: POD: Post-operative day; AHF: Acute heart failure.; f. Mann-Withney U test.
  
 It is statistically significant in POD 2 and POD 
3 when analyzed by the low doses of adrenaline 
(Table 7). 
Table 7: Level of serum NT-proBNP and adrenalin doses 
Time 
Adrenalin 
Post-operative condition 
p-values 
Without AHF AHF 
POD 1 Low dosage (<0.05 µg) 585.3 ± 726.6 2.595 0.12
f
 
Normal doage (≥0.05) 1.444.4 ± 2.911 2.523.9 ± 1.650.3 0.004
f
 
p-values 0.051
f
 1
f
  
POD 2 Low dosage (<0.05 µg) 1.855.6 ± 1.725.2 2.733.8 ± 8.32.3 0.07
f
 
Normal doage (≥0.05) 4.047.4 ± 3.237.4 12.730.8 ± 7.332.3 0.004
f
 
p-values 0.000
f
 0.014
f
  
POD 3 Low dosage (<0.05 µg) 3.140.1 ± 3.890.3 9.095 ± 6.109.4 0.045
f
 
Normal doage (≥0.05) 8.015.2 ± 5.590.9 6.181 0.694 
p-values 0.000
f
 1
f
  
Note: POD: Post-operative day; AHF: Acute heart failure.; f. Mann-Withney U test. 
 
 
 
Discussion  
 
 NT-proBNP reflected the grade of heart failure 
[19] and proved to be useful indicator for evaluating 
heart failure [16] In cardiac surgery, it pointed out as 
independent indicator to predict postoperative 
outcomes [20]. Compared with other indicators, it 
seems to be equal to euroSCORE but superior than 
ejection fraction [21]. It was used in various types of 
cardiac surgery such as percutaneous coronary 
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intervention [22], surgery for aortic stenosis.[23], and 
CABG [11]. As the role of prognosis in CABG patients, 
NT-proBNP in combined with EuroSCORE II provided 
better prognosis accuracy with AUC = 0.93 and the 
cut-off point of NT-proBNP level was 1028 pg/ml [12]. 
When using it alone as an independent indicator to 
predict postoperative mortality, NT-proBNP also 
showed as valuable factor with HR = 2.02 and the cut-
off point was 2,000 pg/ml [24]. To maximize the 
accuracy of NT-proBNP level, the cofounders that 
affected it must be eliminated. In general, factor 
affecting systolic function such as valve disease that 
can be elevated NT-proBNP level through elevating 
filling pressure of left ventricle [6]. Patients with heart 
valve abnormality (aortic or mitral stenosis) often had 
higher pre-operative levels than coronary diseases 
[25]. In our study, there was no patient with 
concomitant valve disease that reduced the risk of 
bias. The other important element affecting NT-
ProBNP level was renal function. The relation 
between them was associated inversely [26] with 
increasing NT-proBNP level as decreasing eGFR [27]. 
Thus, in our study we excluded patients with renal 
function insufficiency to reduce the bias of NT-proBNP 
level. 
 NT-proBNP had shown evidence as a 
predictor of prognosis but what collecting time was 
better to predict also remained unknown [28]. One of 
the most advantages in our study was serial 
measurements of the NT-ProBNP that help to 
optimize the cut off value for specific circumstances. 
Using single NT-proBNP level measured before 
surgery to predict both severe circulatory failure and 
mortality in hospital after surgery [11]. Although 
preoperative measurement was independently 
predictive of postoperative outcome [29], [30], clinical 
assessment combined with biomarker tests also 
showed more useful value [7], [31]. However, 
natriuretic peptides were not included in post-
operation follow-up. To further understanding, 
evaluating NT-proBNP in this period was needed. It 
was more valuable in prediction of mortality when 
using serial measurements within 12 hours [32]. It 
showed as strong predictors for both short-term and 
long-term prognosis [33]. 
 When acute heart failure develops, NT-
proBNP also increases and vice versa. That is why we 
used serum NT-proBNP level as an indicator of follow-
up treatment in this study. It had been proved superior 
to standard care in guiding heart failure treatment with 
cost-effective, improving quality of life, and reversing 
ventricular remodeling [34]. Single NT-proBNP 
measurements can provide a diagnostic index, but it is 
unreasonable for treatment because of disease 
changing rapidly and need to use medical therapy to 
stabilize individual patients directly. Serial NT-proBNP 
measurements may provide intraindividual variation of 
NT-proBNP that reflects the real condition of patients. 
In our study, we used day by day measurements to 
follow continuously.The exact interpretation will lead 
to set up suitable treatment strategies. It can predict 
predicts adverse events during follow-up [35] and from 
that individually optimizing medical therapy for each 
patient [18]. In our study, level of NT-proBNP in AHF 
group was statistically significant compared to the 
without AHF group almost at POD 1 and POD 2 when 
analyzed by the doses of dobutamine, noradrenaline, 
and adrenaline (both low doses and normal doses). 
The dose of inotrope drugs was in line with NT-
proBNP level. These results provide a valuable 
indicator in intensive management after CABG. 
 In conclusion, serial measurement of NT-
proBNP level provides useful prognostic and follow-up 
treatment information in acute heart failure after 
CABG surgery. 
 
 
Ethical approval  
 
 This study is approved by the ethics 
committee of 108 Military Central Hospital.  
 
 
Informed consent 
 
 The consent and commitment were signed by 
the patients in the study 
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